BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update
M Reig, A Forner, J Rimola, J Ferrer-Fàbrega… - Journal of …, 2022 - Elsevier
There have been major advances in the armamentarium for hepatocellular carcinoma
(HCC) since the last official update of the Barcelona Clinic Liver Cancer prognosis and …
(HCC) since the last official update of the Barcelona Clinic Liver Cancer prognosis and …
New advances in the diagnosis and management of hepatocellular carcinoma
JD Yang, JK Heimbach - Bmj, 2020 - bmj.com
Hepatocellular carcinoma is one of the leading causes of cancer related death in the world.
Biannual surveillance for the disease in patients with cirrhosis and in high risk carriers of …
Biannual surveillance for the disease in patients with cirrhosis and in high risk carriers of …
[HTML][HTML] Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a …
LT Chen, E Martinelli, AL Cheng, G Pentheroudakis… - Annals of …, 2020 - Elsevier
The most recent version of the European Society for Medical Oncology (ESMO) Clinical
Practice Guidelines for the diagnosis, treatment and follow-up of hepatocellular carcinoma …
Practice Guidelines for the diagnosis, treatment and follow-up of hepatocellular carcinoma …
[HTML][HTML] Apatinib plus camrelizumab with/without chemoembolization for hepatocellular carcinoma: a real-world experience of a single center
S Ju, C Zhou, C Yang, C Wang, J Liu, Y Wang… - Frontiers in …, 2022 - frontiersin.org
Objective This study was conducted in order to compare the efficacy and safety of
transarterial chemoembolization (TACE) plus apatinib plus camrelizumab (TACE+ AC) and …
transarterial chemoembolization (TACE) plus apatinib plus camrelizumab (TACE+ AC) and …
[HTML][HTML] Comparative effectiveness of different transarterial embolization therapies alone or in combination with local ablative or adjuvant systemic treatments for …
Background The optimal transcatheter embolization strategy for patients with unresectable
hepatocellular carcinoma (HCC) remains elusive. We conducted a systematic review and …
hepatocellular carcinoma (HCC) remains elusive. We conducted a systematic review and …
Morphological, dynamic and functional characteristics of liver pseudolesions and benign lesions
Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths
worldwide and one of the most common causes of death among patients with cirrhosis …
worldwide and one of the most common causes of death among patients with cirrhosis …
[HTML][HTML] Drug-eluting beads transarterial chemoembolization for hepatocellular carcinoma: current state of the art
A Facciorusso - World journal of gastroenterology, 2018 - ncbi.nlm.nih.gov
Transarterial chemoembolization (TACE) represents the current gold standard for
hepatocellular carcinoma (HCC) patients in intermediate stage. Conventional TACE …
hepatocellular carcinoma (HCC) patients in intermediate stage. Conventional TACE …
[HTML][HTML] Transarterial chemoembolization combined with immune checkpoint inhibitors and tyrosine kinase inhibitors for unresectable hepatocellular carcinoma …
F Yang, GL Xu, JT Huang, Y Yin, W Xiang… - Frontiers in …, 2022 - frontiersin.org
Background Locoregional therapy combined with systemic therapy can further improve the
prognoses for HCC. However, the efficacy of TACE combined with ICIs and TKIs for HCC …
prognoses for HCC. However, the efficacy of TACE combined with ICIs and TKIs for HCC …
[HTML][HTML] Multidisciplinary management of recurrent and metastatic hepatocellular carcinoma after resection: an international expert consensus
T Wen, C Jin, A Facciorusso, M Donadon… - … surgery and nutrition, 2018 - ncbi.nlm.nih.gov
Hepatocellular carcinoma (HCC) is the sixth-most common cancer and the third leading
cause of cancer-related death in the world. However, 40–70% patients eventually suffer from …
cause of cancer-related death in the world. However, 40–70% patients eventually suffer from …
[HTML][HTML] The inhibition of ABCB1/MDR1 or ABCG2/BCRP enables doxorubicin to eliminate liver cancer stem cells
Two ATP-binding cassette transporters, ABCB1/MDR1 and ABCG2/BCRP, are considered
the most critical determinants for chemoresistance in hepatocellular carcinoma. However …
the most critical determinants for chemoresistance in hepatocellular carcinoma. However …